Elite Pharmaceuticals, Inc. (ELTP)

Revenue by Segment

Financials in millions USD. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017	Mar 31, 2016
Abbreviated New Drug Applications (ANDA)	84.04M	56.63M	34.16M	32.26M	25.21M
Abbreviated New Drug Applications (ANDA) Growth	48.42%	65.79%	5.87%	27.95%	48.37%
New Drug Applications (NDA)	-	-	-	-	166.17K
New Drug Applications (NDA) Growth	-	-	-	-	-83.38%
Total	84.04M	56.63M	34.16M	32.26M	25.38M
Total Growth	48.42%	65.79%	5.87%	27.11%	41.05%

Revenue by Geography

Financials in millions USD. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017	Mar 31, 2016
United States	84.04M	56.63M	34.16M	32.26M	25.38M
United States Growth	48.42%	65.79%	5.87%	27.11%	41.05%
Total	84.04M	56.63M	34.16M	32.26M	25.38M
Total Growth	48.42%	65.79%	5.87%	27.11%	41.05%

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 20, 2026

Data Sources Report a data error